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S
uccessful management of obesity,
diabetes, and hypertension is a mat-
ter of great urgency in current med-
ical practice because of the soaring
prevalenceofthesethreeinterrelatedcon-
ditions worldwide. Their complications
(ﬁrst and foremost, cardiovascular dis-
ease) result in signiﬁcant morbidity,
which exerts a heavy toll on health care
systems everywhere, especially in indus-
trialized countries. Because the causes
and effects of obesity, diabetes, and hy-
pertension are closely intertwined, pre-
venting their complications requires a
comprehensive approach. Massive re-
search into the etiology and treatment of
these three afﬂictions has recently gener-
ated vast amounts of data, which call into
question many of the accepted treatment
paradigms. They present physicians in
clinical practice with the daily challenges
of integrating innovative therapies into
the treatment protocol, addressing difﬁ-
cult questions and making controversial
decisions.
One of the major dilemmas faced by
physicians in this ﬁeld stems from the re-
cent trials that revealed the relatively
small beneﬁts of blood glucose control in
certain diabetic patients compared with
the possible morbidity and mortality risk.
On the one hand, follow-ups to the Dia-
betes Control and Complications Trial/
Epidemiology of Diabetes Interventions
and Complications Study (DCCT-EDIC)
(1) and the U.K. Prospective Diabetes
Study (UKPDS) (2) have supported the
importance of early diabetes control in
preventing later cardiovascular events
and microvascular complications. More-
over, the STENO-2 Follow-Up Study (3)
fromtheStenoDiabetesCenterinCopen-
hagen demonstrated that early treatment
of cardiovascular risk factors reduces car-
diovascularmorbidityandmortalityyears
later. On the other hand, however, the
results of several trials—the Action in Di-
abetes and Vascular Disease Trial (AD-
VANCE) (4), the Action to Control
Cardiovascular Risk in Diabetes Study
(ACCORD) (5), the VA Diabetes Trial
(VADT) (6), and Heart 2D study (7)—
have cast doubt on the beneﬁts of tight
glucose control in older patients with
longstanding disease (the only exception
being the ADVANCE trial, which demon-
strated the advantages of such control for
blocking the progression of nephropa-
thy). The risks of intensive treatment in
patients with longstanding disease in-
cluded higher mortality in the ACCORD
trial and an increased risk of hypoglyce-
mic events and weight gain in the other
trials. The ﬁndings from these studies
(1–7) have provided clinical evidence for
the concept of “glucose memory,” long
known from basic research (8). This con-
cept calls for revising the currently ac-
cepted approach to optimal glucose
control: it reinforces the importance of
achieving normal glucose levels immedi-
ately upon the diagnosis of diabetes for
preventing later-onset complications.
Early control, aiming at normoglycemia,
is easily attained and involves the use of
relatively safe drugs (metformin, acar-
bose), with small risk of major side ef-
fects. Physicians who delay achieving
early normoglycemia cause their patients
more harm than good, since aiming at
glucose control in the later stages of dia-
betesmayputthepatientsatagreaterrisk
with marginal beneﬁts.
The second World Congress on Con-
troversies to Consensus in Diabetes, Obe-
sity and Hypertension (CODHy), held in
Barcelona at the end of October 2008,
brought together leading international
experts with the goal of discussing the
mostpressingcontroversiesinthesethree
disciplines and reaching a consensus on
treatment guidelines for the coming 2
years. To achieve this goal, the Congress
included state-of-the-art lectures and re-
ports on the latest clinical studies, as well
as numerous debates and discussions in
which internationally prominent physi-
cians shared their clinical expertise with
the meeting participants. The present
supplement, divided into six sections,
provides highlights from the meeting, in-
cluding summaries of lectures and the
contents of major debates held at the
Congress.
Thesectionondiabetesopenswithan
overview of the pathophysiology of dis-
easeprogression.Italsodwellsonwaysin
which the development of diabetes is af-
fected by two major characteristics: insu-
lin resistance in different target organs
and the failure of -cells to secrete ade-
quateamountsofinsulinduetotheshort-
age or defective function of these cells.
The combination of these two character-
istics, leading to micro- and macrovascu-
lar hyperglycemic damage, raises
important questions with respect to the
targets for glycemic control: Should phy-
sicians concentrate on A1C or attempt to
prevent postprandial hyperglycemia?
Special emphasis was placed at the Con-
gress on the role of nonpharmacological
approaches in preventing diabetes and in
treating newly diagnosed diabetes. The
signiﬁcance of early pharmacological in-
tervention was also noted. In fact, aiming
at establishing normoglycemia in the
early stages of diabetes, to prevent the
emergence of “glucose memory” in later
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proachtothetreatmentoftype2diabetes.
In this context, meeting participants de-
bated the optimal ways of monitoring
blood glucose levels, in particular, the
roleofself-controlofbloodglucoseasop-
posed to continuous glucose monitoring
in the treatment of patients with type 1
and type 2 diabetes.
Several lectures and debates dealt
with novel therapies of diabetes—
including incretin-based therapy, bile
acid metabolic regulation, and an innova-
tivetherapyforlatentautoimmunediabe-
tesinadults—aswellaswithpotentialuse
of antioxidant and anti-inﬂammatory
treatments in diabetes. Speakers dis-
cussed the best ways of incorporating
novel therapies into the treatment regi-
men and debated whether the new ap-
proaches had created a need for a new
paradigm in the treatment of diabetes.
Furthermore, a signiﬁcant part of this
supplement is devoted to insulin therapy
for type 2 diabetes: the ideal timing for
starting such therapy and ways of admin-
isteringitintheearlyandlatestagesofthe
disease.
This supplement’s second section on
hypertension covers the management of
hypertension in patients with diabetes.
What is the deﬁnition of prehypertension
indiabetes?Shouldthisborderlinecondi-
tion be treated in diabetic patients? How
should the treatment approach differ be-
tween diabetic and nondiabetic patients?
The need for 24-h monitoring of blood
pressure in diabetes is also discussed. Yet
another topic in this section relates to the
risks of white coat hypertension and the
pros and cons of treating it in diabetic
patients.
Theconnectionbetweendiabetesand
cardiovascular disease forms the content
of the third section. Because diabetes dis-
rupts endothelial function and otherwise
contributes to the appearance of cardio-
vascular disease, the control of blood glu-
cose levels can play an important role in
preventing cardiovascular disease. How-
ever, other cardiovascular risk factors are
easier to treat than hyperglycemia, and
they can be improved with less deleteri-
ous side effects. In light of this, what are
the relative advantages and disadvantages
of hyperglycemia treatment for the pre-
vention of cardiovascular disease? This
section provides conclusions drawn from
large studies aimed at achieving normo-
glycemia and discusses the advantages or
disadvantages of various hyperglycemic
drugs in the prevention of cardiovascular
events.
The fourth section, on obesity and
lipids, deals with weight gain as a health
risk factor for people of all ages, as well as
with the need to control various compo-
nents of dyslipidemia other than LDL
(particularly HDL and triglycerides) in
the management of obese diabetic pa-
tients.Thesectionincludesadetaileddis-
cussion on the recommendations of the
AmericanDiabetesAssociationfortheuse
of statins in patients with diabetes; evi-
dence from clinical trials suggests that
these guidelines might have to be broad-
enedtoencompassawidersegmentofthe
population. In addition, the section dis-
cusses the role of weight control in the
treatment of diabetes. Is weight reduction
beneﬁcial in the elderly diabetic patient?
Should clinicians concentrate on weight
control or physical activity in averting the
risk of cardiovascular disease? Highlights
of the debates on these topics are
provided.
Diagnosis and treatment of microvas-
cular disease is discussed in the ﬁfth sec-
tion. One important issue is the use of
singleordoublerenin-angiotensinsystem
blockade in preventing microangiopathy
intheeyeandkidney.Othercommonmi-
crovascular complications are discussed,
includingdetailedreviewsofpainfulneu-
ropathy and impotence, both affecting
50% of patients with diabetes.
The topic of the ﬁnal sixth section of
this supplement is smoking. This addic-
tive behavior ampliﬁes the risk of cardio-
vascular complications in patients with
diabetesandhypertension,yetgettingpa-
tients to quit smoking is frustratingly dif-
ﬁcult. Articles in this section outline the
psychological and physiological factors
contributing to this difﬁculty and stress
the importance of smoking cessation at
any age.
Controversies can serve as a major
driving force of progress, since they stim-
ulate thought, discussion, and the yearn-
ing for more knowledge. In focusing on
controversies relevant to clinical practice
rather than basic research, the Congress
was intended to promote progress in pa-
tient care. Reﬂecting the design of the
meeting, this supplement aims to provide
physicians treating people with diabetes,
hypertension, and obesity with the most
up-to-date information that can help
them make the optimal evidence-based
decisions in their daily practice.
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